NLRP3 and metabolic disease: Glucose, fatty acids, and islet amyloid polypeptide activate the NLRP3 inflammasome driving to metabolic disorders, T2D, and secondary CMS by pancreatic islet inflammation and subsequent β-cell failure and destruction [57,58,59].